Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults

NCT01767402 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01767402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2003
Completion date
November 30, 2004
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease